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Abstract
A peptidase-resistant ABL kinase substrate was developed by identifying protease-susceptible 
bonds on an ABL substrate peptide and replacing flanking amino acids with non-native amino 
acids. After an iterative design process, the lead, or designed, peptide X-A possesses a six-fold 
longer life in a cytosolic lysate than that of the starting peptide. The catalytic efficiency (kcat/KM) 
of purified ABL kinase for the lead peptide (125 s−1 μM−1) is similar to that of the starting peptide 
(103 s−1 μM−1) demonstrating preservation of the peptide’s ability to serve as a kinase substrate. 
When incubated in cytosolic lysates, the lead peptide is slowly degraded into 4 fragments over 
time. In contrast, when loaded into intact cells, the peptide is metabolized into 5 fragments, with 
only 2 of the fragments corresponding to those in the lysate. Thus the two environments possess 
differing peptidase activities, which must be accounted for when designing peptidase-resistant 
peptides. In both settings, the substrate is phosphorylated by BCR-ABL providing a readout of 
BCR-ABL activity. A small panel of tyrosine kinase inhibitors verified the substrate’s specificity 
for BCR-ABL/ABL kinase activity in both lysates and cells in spite of the multitude of other 
kinases present. The designed peptide X-A acts as a long-lived BCR-ABL kinase reporter in the 
leukemic cells possessing the BCR-ABL mutation.
INTRODUCTION
Philadelphia chromosome positive (Ph+) cancer stem cells are a hallmark of chronic 
myelogenous leukemia (CML), with over 90% of CML patients expressing Ph+ cells.1-6 The 
Ph chromosome results from a reciprocal translocation between the breakpoint cluster region 
(bcr) of chromosome 22 and the Abelson tyrosine kinase (abl) region of chromosome 9, 
forming a gene that encodes the fusion protein BCR-ABL. During the translocation event, 
the regulatory domain of ABL, normally located upstream of the kinase domain, is replaced 
by BCR, causing BCR-ABL to be constitutively active.4,7,8 BCR-ABL hijacks the ABL 
pathway, resulting in, among other processes, increased proliferation and decreased 
apoptosis of cells possessing BCR-ABL.4,8,9 The dependence of CML on BCR-ABL made 
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it an ideal target for the first small molecule inhibitor specifically targeting a known 
oncogene.10-13 Imatinib mesylate competes with ATP to bind in the catalytic domain of 
BCR-ABL to prevent the phosphorylation of BCR-ABL substrates.10,14 As a front-line 
therapy, imatinib has been hugely successful, with an 8-year follow up of Phase III testing 
demonstrating 85% overall survival for imatinib-treated CML patients.1,8 However, 
resistance to imatinib often develops, typically from acquired resistance that arises from one 
or more point mutations in the kinase domain.8,9,15 Second and third generation inhibitors 
(i.e. dasatinib, ponatinib) have been developed to overcome these mutations, but are not 
usually considered until imatinib has failed.8,9,16,17 Furthermore, there is a small subset of 
CML patients who lack Ph+ cancer stem cells and do not benefit from therapies targeting 
these cells.4,8 As therapy can be costly both financially and in terms of secondary health 
effects, it would be beneficial to measure both the biochemical activity of BCR-ABL and the 
sensitivity of patient cells to the inhibitor to direct optimal therapeutic choices and to 
monitor treatment.
Historically, BCR-ABL has been detected by the presence of the bcr-abl fusion gene using 
techniques such as chromosome banding and fluorescence in situ hybridization (FISH).18-21 
The cost, time, labor, and expertise required for these techniques and their limited sensitivity 
and specificity have driven the adoption of other methods for detection of bcr-abl in the 
clinical setting.19 Genotyping technologies, such as traditional Sanger sequencing, 
microarray based screening, PCR-based techniques, and next-generation sequencing (NGS) 
are now supplanting these older approaches.17,19,22-25 NGS has many benefits over the other 
genotyping technologies in detecting base substitutions, insertions, deletions, copy number 
alterations, and translocations and the cost per base pair is less than that of the more 
traditional techniques.22 NGS can often detect lower copy numbers of bcr-abl mutants, 
providing an advantage in revealing the appearance of inhibitor-resistant mutations earlier 
than other techniques.24 Protein detection techniques, such as mass spectrometry and flow 
cytometry, have been utilized to monitor BCR-ABL, but have not yet become mainstream 
clinical techniques.26-29 The use of fluorescent antibodies against BCR-ABL, or its 
phosphorylated substrates (phospho-flow), have been employed in flow cytometry to 
characterize the presence of BCR-ABL on a cell-by-cell basis in both cell lines and patient 
samples.28,29 A drawback in the above-mentioned techniques is that while detecting the 
presence of the fusion gene or its protein product, the methods do not quantitatively measure 
the biochemical activity of BCR-ABL. While phospho-flow can be used to measure the 
presence of a phosphorylated BCR-ABL substrate, such as CRKL, even this technique is 
unable to detect constitutively or transiently active enzyme through quantification of 
substrate and product. A technique that quantifies the biochemical activity of BCR-ABL 
coupled with the capability to reliably analyze clinical samples, which typically contain a 
relatively small number of patient cells, would be of utility in assessing the likelihood of 
patient response to therapy.
Herein we describe the development of a rationally designed BCR-ABL peptide substrate 
that serves as a reporter for the direct quantification of BCR-ABL activity in cellular lysates 
and within intact cells.30 Our design strategy utilizes non-native amino acids incorporated 
into the reporter at specific loci to impart stability to a peptide substrate that is otherwise 
rapidly degraded by intracellular proteases. Non-native amino acids are often used to expand 
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the chemical properties available for proteins and peptides by selectively altering individual 
residues to feature properties not attainable with native amino acids.31,32 Furthermore, non-
native amino acids can serve as structural building blocks, conformational constraints, and 
protease-resistant residues in pharmacologically active agents, such as for enzymatic 
inhibitors and long-lived bioactive peptides.33,34 It is this ability of non-native amino acids 
to stymie protease activity on peptides and proteins that led to their use in our generation of 
the peptidase-resistant BCR-ABL reporter described here.
Capillary electrophoresis separates analytes based on differences in electrophoretic 
mobilities, with analyte mass, shape, and charge all impacting this parameter.35 The 
background electrolyte (BGE) utilized as the electrophoretic buffer can be finely tuned by 
adjusting the salt species, concentration, and pH or by addition of additives such as 
detergents or organics to influence net analyte charge or mobility. Proper BGE selection 
typically yields peaks with very little band-broadening, translating to a high peak capacity 
and the ability to separate structurally-related analytes. In this work, the exquisite sensitivity 
and peak capacity of capillary electrophoresis coupled with laser-induced fluorescence 
detection (CE-LIF) permits the identification of proteolytic-susceptible peptide bonds due to 
the single-amino-acid resolution easily achieved by the CE-LIF technique. The optimized 
reporter serves as a robust BCR-ABL kinase reporter in both cellular lysates and within 
single cells with minimal degradation by intracellular proteases. Finally, cells pretreated 
with pharmacologic inhibitors were assayed for BCR-ABL activity to demonstrate the 
ability to analyze the relative effectiveness of individual inhibitors on BCR-ABL activity in 
living cells. Such data is aimed toward the idea of personalizing treatment options based on 
the unique biochemical phenotype of a specific patient’s tumor.
MATERIALS AND METHODS
Materials
5-carboxyfluorescein (5-FAM), 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate (HCTU), 9-fluorenylmethoxycarbonyl (Fmoc) 
amino acids, and the resins were purchased from ChemPep (Wellington, FL) and 
Novabiochem (San Diego, CA). N-Hydroxybenzotriazole (HOBt) was obtained from 
AnaSpec. Abl-1 human recombinant protein was obtained from Life Technologies 
(Carlsbad, CA). PTP1B inhibitor and bovine serum albumin (BSA) were purchased from 
Calbiochem (San Diego, CA). All other reagents for peptide synthesis and biochemical 
assays were ordered from Sigma-Aldrich (St. Louis, MO) or ThermoFisher Scientific 
(Waltham, MA). Cell culture reagents were procured as follows: Roswell Park Memorial 
Institute Media (RPMI-1640) from Cellgro (Manassas, VA), penicillin/streptomycin from 
Gibco (Grand Island, NY) and fetal bovine serum (FBS) from Atlanta Biologicals (Flowery 
Branch, GA). The Baf/BCR-ABL murine cell line expressing BCR-ABL kinase was 
obtained from Dr. Brian Druker’s lab at Oregon Health and Science University. Sodium 
orthovanadate and hydrogen peroxide were purchased from Sigma-Aldrich (St. Louis, MO). 
The kinase inhibitors dasatinib, masitinib, and sunitinib were obtained from LC Laboratories 
(Woburn, MA) and imatinib was purchased from Sigma (St. Louis, MO).
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Peptide synthesis and purification
Full-length peptides and peptide fragment standards were synthesized by Fmoc solid phase 
peptide synthesis (Prelude peptide synthesizer, Protein Technologies, Tucson, AZ) as 
described previously30 using a TentaGel Rink (TGR) resin for peptides amidated on the C-
terminus and a 2-chlorotrityl chloride resin for peptide standards with a free carboxylic acid 
on the C-terminus. All peptides were labeled with 5-FAM at the N-terminus and purified via 
HPLC equipped with a 2489 UV/Visible detector (Waters 1512 Binary HPLC, Milford MA) 
and an Apollo 250 × 22 mm C18 column (5 μm particles; Grace, Columbia, MD) using a 
gradient of acetonitrile:water (3%-60%) with 0.1% trifluoroacetic acid. Peptide mass was 
confirmed by an Agilent 1200 series LC-MS with a 6110 Quadropole LC/MS detector 
(Agilent, Santa Clara, CA).
Cell Culture
Baf/BCR-ABL cells are a mouse B-cell lymphoma line that was stably transfected with and 
overexpresses BCR-ABL protein.11 Baf/BCR-ABL cells were grown in RPMI-1640 media 
supplemented with 10% FBS, penicillin (100 units mL−1), and streptomycin (100 mg mL−1). 
The cells were kept in a humidified atmosphere of 37 °C with 5% CO2 and were passaged 
into fresh media every 3-4 days.
Capillary electrophoresis
In vitro assay samples were analyzed by capillary electrophoresis coupled with laser-
induced fluorescence detection (CE-LIF; 488 nm) using a ProteomeLab PA800 (Beckman 
Coulter, Fullerton, CA). Fused silica capillaries (Polymicro Technologies, Phoenix, AZ) 
with an inner diameter of 50 μm, outer diameter of 360 μm, effective length of 20 cm, and a 
total length of 30 cm were pre-conditioned by rinsing sequentially with 1 M NaOH for 12 h, 
H2O for 1h, 0.1 M HCl for 6 h, and H2O for 12 h. Samples were diluted in the appropriate 
electrophoretic buffer to a final concentration of 50-250 nM prior to analysis. Capillaries 
were rinsed between each run with 1 M NaOH, H2O, and buffer for 2 min by applying a 
pressure of 20 psi to the capillary inlet. Sample was hydrodynamically loaded into the 
capillary by applying 0.5 psi to the capillary inlet for 5 s and electrophoresis was initiated by 
applying a negative voltage to the outlet. For lysate samples, the voltage applied was 500 V 
cm−1 and for in vitro kinase assay samples, the voltage applied was 600 V cm−1. The data 
was processed using commercial software (32 Karat, version 8.0, Beckman Coulter, 
Fullteron, CA) and represented graphically using Origin software (version 9.0, OriginLab 
Corporation, Northampton, MA).
The undiluted bulk lysate from cells pinocytically loaded with peptide was analyzed with a 
custom-built CE-LIF system as previously described in detail.36 Capillaries were pretreated 
before use as described above and possessed a total length of 38 cm with an effective length 
of 20.5 cm and an inner diameter of 30 μm. The electrophoretic buffer was 100 mM tris, 100 
mM tricine, pH 8.8 and a field strength of 210.5 V cm−1 was applied across the capillary for 
separations. Electrophoresis was initiated by applying a negative voltage to the capillary 
outlet while the inlet was held at ground. The data was analyzed and represented graphically 
using Origin 9.0 software.
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Peptide degradation in a cellular lysate
The Baf/BCR-ABL cells were rinsed with and resuspended in phosphate buffered saline 
solution (PBS; 137 mM NaCl, 10 mM NaH2PO4, 27 mM KCl, 1.75 mM KH2PO4, pH 7.4), 
and then lysed using three freeze-thaw cycles. The supernatant was collected after 
centrifugation and total protein concentration was determined using fluorescamine.30 For 
assays, cytosolic lysate (3 mg mL−1 total protein) was incubated with 1 μM peptide substrate 
at 37 °C. Aliquots were collected at different time points and the reaction inactivated with 
twice the aliquot volume of 200 mM HCl. A 0 min time point was prepared by inactivating 
the lysate with HCl prior to adding the peptide. Samples were diluted in the electrophoretic 
buffer (100 mM tris, 100 mM tricine, pH 8.1) to a final concentration of 50 nM peptide and 
analyzed by CE-LIF as described above. Migration times of proteolytic fragments were 
determined by sequentially adding each known fragment standard to the lysate samples and 
performing electrophoresis to identify unknown peaks. Triplicate measurements were 
performed using different cytosolic lysates.
In vitro phosphorylation by purified kinase
Experiments were performed in triplicate by incubating a mixture of 29 μM fluorescently 
labeled peptide and 12 nM recombinant Abl-1 kinase in assay buffer (50 mM tris, 1 mM 
MnCl2, 5 mM MgCl2, 2 mM DTT, 1 mM ATP, pH 7.4) at 30 °C. Aliquots were collected at 
varying time points and the enzyme was inactivated by heating the mixture at 95 °C for 4 
min. In addition, negative control samples without ATP were simultaneously collected. The 
aliquots were diluted in electrophoretic buffer (100 mM tris, 100 mM tricine, 5 mM SDS, 
pH 8.1) to a final peptide concentration of 60 nM and the amount of peptide reactant and 
product was quantified with CE-LIF. Peptide standards phosphorylated to completion were 
generated by incubating 29 μM substrate with 36 nM Abl-1 kinase in assay buffer at 30 °C 
for 4 h. The mixture was inactivated by incubation at 95 °C for 4 min and complete 
phosphorylation was confirmed by CE-LIF. Peaks on electropherograms were identified by 
co-mixing phosphorylated and non-phosphorylated peptide standards with samples.
Determination of kinetic parameters
The immobilized metal ion affinity-based fluorescent polarization (IMAP) assay (Molecular 
Devices, Sunnyvale, CA) was used to quantify the amount of phosphorylated peptides 
following the manufacturer’s instructions. Kinase assays were performed as described above 
with the following modifications: enzyme concentration was 6 nM and peptide concentration 
varied from 10 to 100 μM. For the IMAP assay, the samples were diluted to 100 nM with a 
buffer composed of 10 mM tris-HCl (pH 7.2), 10 mM MgCl2, and 0.01% Tween-20. The 
amount of phosphorylated peptide was calculated based on a calibration curve obtained from 
measurements on co-mixtures of phosphorylated and non-phosphorylated peptide. A 
fluorescence plate reader (SpectrMax M5, Molecular Devices, Sunnvale, CA) with an 
excitation of 485 nm and emission of 525 nm was used.
Peptide phosphorylation in cellular lysates
Baf/BCR-ABL cells were rinsed twice with PBS and resuspended in the lysis buffer 
[Mammalian Protein Extraction Reagent (M-PER; Thermo Scientific, Waltham, MA) and 
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100 μM sodium pervanadate)]. No phosphorylation of peptide X-A was observed in the 
absence of the pan-phosphatase inhibitor, sodium pervanadate (data not shown) presumably 
due to the unrestrained activity of phosphatases under these conditions. Control experiments 
were performed using the same lysis buffer, but with 100 μM imatinib added. The mixture 
was agitated for 10 min, the supernatant collected by centrifugation, and total protein was 
determined by reaction with fluorescamine and comparison to standards of BSA. The 
reaction mixture comprising Baf/BCR-ABL cytosolic lysate (10 mg mL−1 total protein), 
reaction buffer (50 mM tris, pH 7.5, 1 mM MnCl2, 5 mM MgCl2, 2 mM DTT, 1 mM ATP) 
and peptide was incubated at 30 °C. Aliquots were collected at varying times and enzymes 
inactivated with an equal volume of 200 mM HCl. An initial 0 min time point was prepared 
by inactivating enzymes with HCl before adding the peptide. Samples were diluted in 
electrophoretic buffer (100 mM tris, 100 mM tricine, pH 8.1) to a final concentration of 250 
nM and analyzed by CE-LIF. Triplicate measurements were performed by using different 
cytosolic lysates.
Peptide phosphorylation in intact cells
Baf/BCR-ABL cells were loaded with peptide X-A using pinocytosis following the 
manufacturer’s instructions (Influx, ThermoFisher Scientific, Waltham, MA.) 5 × 106 Baf/
BCR-ABL cells were incubated for 1 h at 37 °C in 1 mL of complete growth media 
supplemented with inhibitor or 1% DMSO as a control. Inhibitor concentrations were 50 μM 
imatinib, 15 nM dasatinib, 1 μM masitinib, or 300 nM sunitinib, with stock concentration 
diluted in DMSO such that the total DMSO amount in the media added to the cells was 
1%.37-40 The cells were loaded with peptide X-A by incubating for 10 min at 37 °C in 
hypertonic loading solution containing 100 μM peptide X-A, 1 mM sodium pervanadate, and 
50 μM PTP1B phosphatase inhibitor (25 μL per 5 × 106 cells.) Pinosomes were lysed in 
hypotonic RPMI-1640, releasing peptide X-A into the cytosol and initiating the biochemical 
reactions. Cells were transferred to complete growth media supplemented with tyrosine 
kinase inhibitor, 1 mM sodium pervanadate, and 50 μM PTP1B phosphatase inhibitor and 
allowed to recover for 10 min at 37 °C. After recovery, cells were washed twice with PBS 
and the reactions terminated by heating at 95 °C for 5 min. The total time that peptide X-A 
was in viable cells was 25 min. The cell lysate was clarified by pelleting at 14,000 × g for 15 
min. The supernatant, containing the biochemical reaction products, was collected and 
stored at −20 °C until immediately prior to CE analysis as described in the above “Capillary 
electrophoresis” section. Triplicate measurements were performed using different Baf/BCR-
ABL cells.
RESULTS AND DISCUSSION
Optimization and characterization of an ABL kinase substrate
The ABL kinase substrate V-48B was previously rationally designed from an ABL substrate 
by sequential substitution of non-native amino acids to enhance resistance to protease 
degradation (Table 1).30 While V-48B exhibits a 15-fold improved half-life in the face of 
cellular proteases relative to its parent sequence III-67B (Table 1), V-48B’s degradation 
resistance is insufficient for kinase activity measurement when faced with the high 
concentration of peptidases within an intact cell. This is primarily due to hydrolysis of the 
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peptide bond between the two alanine residues. We sought to enhance the protease resistance 
of V-48B while maintaining its ability to act as an ABL substrate by replacement of the 
labile bond’s flanking residues. In past work by others, three non-native amino acids 
chemically similar to alanine [sarcosine, D-alanine, and (N-methyl)alanine] were 
demonstrated to impart peptide resistance to hydrolysis.41-43 These residues impart 
resistance by either chemically modifying or reorienting the peptide backbone so that the 
peptidases no longer access or make appropriate contacts with the targeted peptide bond 
(Supplemental Figure S1).
Three peptides were synthesized with the amino-terminal alanine residue replaced by (N-
methyl)alanine, sarcosine, or D-alanine (peptides VII-A, VII-B, and VII-C, Table 1). The 
peptides were incubated in a Baf/BCR-ABL cytosolic lysate and after varying times, 
aliquots were removed from the reaction mixture and assayed by CE. Over the course of 60 
min, the parent peptides VII-A, VII-B, and VII-C were degraded into an additional 3, 3, and 
4 peptides, respectively (Supplemental Figure S2). The percentage of intact peptide was 
plotted over time and the half-life (t1/2) in the lysates calculated (Supplemental Figure S2, 
Table 1). The t1/2 of the series VII peptides were similar to or poorer than that of peptide 
V-48B, indicating that the amino acid modifications do not prevent degradation by proteases. 
Indeed, sarcosine and (N-methyl)alanine undesirably improves the peptide’s suitability as a 
substrate for proteases relative to that of the starting peptide.
The ABL consensus sequence demonstrates a strong preference by the kinase for an alanine 
at the substitution site for the series VII peptides.44 Whether this preference extended to 
alanine mimics (and potentially to non-native residues other than those assayed) was unclear. 
Before targeting this site for additional modifications, we sought to determine if the ABL 
kinase would tolerate substitutions at this site. Each peptide was incubated with purified 
ABL-1 kinase in vitro and phosphorylation was measured over time (Supplemental Figure 
S2). In all cases, none of the modified peptides demonstrated evidence of phosphorylation 
over the 120 min incubation, suggesting that even modifications with alanine-like residues at 
this location are intolerable to the kinase. Due to the lack of degradation resistance and poor 
substrate efficacy of the series VII peptides, substitutions at the alanine amino-terminal to 
the hydrolysis site were not pursued.
Characterization of peptides following replacement of the alanine carboxy-terminal to the 
hydrolysis site
In the second round of modifications, the alanine on the carboxy-terminal side of the 
susceptible bond was substituted with (N-methyl)alanine, sarcosine, or D-alanine (peptides 
VIII-A, VIII-B, and VIII-C, Table 1). These peptides were assessed for resistance to 
degradation by incubation in a Baf/BCR-ABL cytosolic lysate. After 60 min in the lysate, 
peptides VIII-A and VIII-C were metabolized into 5 peptide fragments and VIII-B into 4 
fragments (Supplemental Figure S3). The (N-methyl)alanine (VIII-A) and sarcosine (VIII-
B) substituted peptides were more stable than the parent peptides, with 22 ± 8% of intact 
VIII-A and 43 ± 10% of intact VIII-B remaining after 60 min (Figure 1A). The t1/2 of 
peptides VIII-A and VIII-B are 1.3- and 2.5-fold longer, respectively, than that of the parent, 
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V-48B (Table 1). The D-alanine-substituted peptide (VIII-C) did not exhibit an improved 
resistance to hydrolysis.
The consensus sequence for ABL substrates indicates a very slight preference for alanine at 
the substituted alanine in the series VIII peptides, suggesting that residues similar to alanine 
may be tolerated by the kinase at this location. The series VIII peptides were incubated with 
purified ABL-1 kinase (Figure 1B, Table 1) followed by measurement of phosphorylated 
peptide. Peptide VIII-C is minimally phosphorylated, indicating that a D-isomer in this 
position is not favored by the kinase, likely due to positioning of the side chain on the 
opposite side of the substrate. Peptides VIII-A and VIII-B were phosphorylated 6× and 1.5× 
faster than V-48B, respectively, suggesting that backbone modifications due to these two 
non-native amino acids do not alter the substrate’s binding in the kinase’s active site. Since 
VIII-B possesses the best protease resistance of the series VIII peptides while still remaining 
a good ABL substrate, VIII-B was further optimized.
Characterization of the peptide VIII-B fragments formed in a Baf/BCR-ABL cytosolic lysate
Although the sarcosine-containing peptide VIII-B displays a much longer lifetime in the 
cytosolic lysate than peptide V-48B, VIII-B was still degraded over time into four fragments. 
To determine which locations were susceptible to hydrolysis, all possible fluorescent peptide 
fragments were synthesized and characterized by electrophoresis. Under the electrophoretic 
conditions utilized, all of the fragment peptides were resolved from each other as well as 
from the intact parent peptide. Peptide VIII-B was incubated in a Baf/BCR-ABL lysate and 
each of the possible fluorescent peptide standards were sequentially added to the mixture to 
identify the unknown peaks in the electropherogram. The percentage of intact and 
fragmented peptide was then plotted as a function of time (Supplemental Figure S4). The 
11-residue peptide is the first initial fragment formed, appearing at a rate of 0.04 zmol pg−1 
s−1, nearly equal to that of the degradation rate of the intact peptide. This fragment is formed 
by removal of the alanine residue at the end of the peptide. Three other fragments, 2-, 5-, 
and 9-residue peptides, also formed, but in very low amounts relative to that of the 11-
residue fragment. In the initial peptide V-48B, the most abundant fragment was the 5-residue 
peptide, which formed at a rate of 0.11 zmol pg−1 s−1. In peptide VIII-B, this same 5-residue 
peptide fragment forms at a rate of 0.002 zmol pg−1 s−1, approximately 55× slower, 
suggesting that conversion of the alanine to a sarcosine successfully blocks the proteases 
acting on the peptide bond between the two alanine residues.
Characterization of the 11-residue fragment of VIII-B as an ABL reporter
Peptide IX-A, identical to VIII-B but without the alanine residue at the C-terminus (Table 1), 
was assayed for resistance to proteolysis in a cell lysate. Unexpectedly, peptide IX-A 
degrades 1.5× faster than VIII-B with only 32 ± 3% of the peptide intact after 60 min 
(Figure 2.) In addition to the parent peptide, four peaks were observed on the 
electropherogram after 60 min and three of these peaks match the migration times of 
fragment peaks derived from peptide bond hydrolysis. However, the dominant fragment (43 
± 2% of all peptide) was not the result of peptide bond hydrolysis between two amino acids. 
Instead, this peptide is formed by conversion of the C-terminus carboxamide to the 
corresponding carboxylate, which was verified by comparison of the migration time of the 
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synthesized standards. This result is surprising since deamidation was not observed for any 
of the prior peptides or for other kinase substrate peptides.30,45 However, peptide 
deamidation does occur in biological peptides and proteins, though it is most often 
associated with the polar non-charged residues of asparagine and glutamine, and not lysine 
as observed here.46,47 Deamidation typically depends on multiple attributes such as 
sequence and 3D structure, and is thought to be a post-translational modification that 
increases in incidence with organism age.47
The consensus sequence for ABL substrates is weighted toward those residues nearest to the 
phosphorylatable residue, with an isoleucine preferred at the −1 position, an alanine strongly 
preferred at the +1 position, and a proline preferred at the +3 position, relative to the 
phosphorylatable tyrosine.44 No sequence preference is indicated at the +8 position 
suggesting that removal of the single terminal residue from peptide VIII-B to form IX-A 
might not diminish the ABL substrate properties of IX-A relative to that of VIII-B. When 
incubated with purified ABL-1 kinase, peptide IX-A demonstrated a t50% P 2.8× better than 
that of peptide VIII-B (Figure 3, Table 1). The excellent ABL substrate properties of peptide 
IX-A and tolerance of the kinase for modifications at the C-terminus suggests that removal 
of the amidated terminus might yield an ABL reporter with increased protease resistance.
Characterization of the lead peptide X-A
Peptide X-A (identical to fragment xi from IX-A) was formed by removal of the amidated 
terminus of IX-A. Peptide X-A was incubated in a cytosolic lysate and its resistance to 
degradation in a cytosolic lysate quantified. The t1/2 of X-A is 3.4× longer than that of 
peptide IX-A and nearly 6× longer than that of the starting peptide V-48B (Figure 3, Table 
1). Peptide X-A was minimally degraded over the 60-min time span of the experiment with 
formation of small quantities of 4 fragments, the 5-, 4-, 2-, and 1-residue peptides (Figure 4). 
The 5-residue peptide (cleavage at the Ala-sarcosine bond) formed in the greatest quantity, 
representing 17 ± 0.6% of all peptide at 60 min, forming with an initial rate of 0.012 zmol 
pg−1 s−1, 10× slower than it formed in the starting peptide V-48B. Thus this peptide bond 
continued to be protected by the sarcosine residue. Peptide X-A is the longest lived peptide 
in this small-scale library in spite of its free carboxylate terminus. Biologically, greater than 
50% of peptides are amidated via post-translational modifications in order to attain their 
maximum activity.48,49 Synthetic peptides are often amidated to mimic this biological reality 
and to impart some protection of the peptide from exopeptidases.50 However, in this case, 
removing the carboxamide moiety from peptide X-A actually improved its resistance to 
degradation. The positively-charged lysine residues at the C-terminus of peptides is often 
cleaved by carboxypeptidase B, a mammalian enzyme,51 suggesting that this enzyme (and 
other similar enzymes) may not be highly active in these cells since the unprotected C-
terminal lysine is relatively stable.
Peptide X-A was incubated with purified ABL-1 kinase in vitro, and aliquots were removed 
over time to quantify phosphorylation. Peptide X-A was phosphorylated 4× slower than 
precursor peptide IX-A and 2.4× slower than the starting peptide V-48B (Figure 3B). The 
free carboxylate of X-A adds a negatively charged terminus to the peptide. Abl kinase does 
not have a strong amino acid preference at this location (+7 relative to the tyrosine residue) 
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on its native substrates and tolerates amino acids with negatively charged side chains in this 
position.52 However, the +7 residue on a fully folded protein may be positioned so that no 
contact is made with the kinase, accounting for the tolerance of negatively charged residues 
at this position. In contrast, the +7 residue of an unstructured peptide is expected to be in 
proximity to the kinase surface for some fraction of time due to random molecular motions, 
and may be the cause of the decreased substrate phosphorylation.
To quantitatively compare the substrate suitability of the rationally designed peptide X-A to 
the starting peptide V-48B, their kinetic parameters were measured. Peptide X-A displays an 
improved KM relative to that of peptide V-48B (15 ± 6 μM compared to 23 ± 6 μM), but 
suffers from a diminished turnover number (kcat of 1,875 min−1 for peptide X-A compared 
to 2,375 min−1 for peptide V-48B). However, the catalytic efficiency as evidenced by the 
kcat/KM is very similar for X-A (125 s−1 μM−1) relative to that of V-48B (103 s−1 μM−1). 
Furthermore, peptide X-A possesses a 6× improved resistance to degradation relative to 
V-48B, suggesting that X-A might act as a better reporter for Abl kinase in the presence of 
cytosolic proteases.
Peptide X-A as a reporter of BCR-ABL activity in cytosolic lysates
We next tested whether peptide X-A serves as a reporter of BCR-ABL activity in a cytosolic 
lysate while still resisting proteolytic degradation. Cell lysates are a cost-effective way to 
generate a reaction environment containing the native enzyme along with co-factors and 
regulatory elements found in the cell. Furthermore, both substrate and any inhibitors which 
are not cell-membrane permeant are readily assayed. Peptide X-A was incubated in a Baf/
BCR-ABL lysate and aliquots removed over time and analyzed with CE-LIF to quantify 
peptide phosphorylation and degradation. X-A is readily phosphorylated in the lysate 
(Supplemental Figure S5B). When the lysate was incubated with the BCR-ABL kinase 
inhibitor imatinib prior to the addition of X-A, the degradation profile remained the same but 
phosphorylation was reduced to nearly zero, demonstrating that the phosphorylation of this 
peptide was accomplished by a kinase sensitive to imatinib, likely BCR-ABL. These results 
indicate that peptide X-A acts as a reporter of BCR-ABL activity in these cell lysates.
Peptide X-A as a reporter of BCR-ABL kinase activity within intact cells
We evaluated peptide X-A as a reporter of BCR-ABL activity in intact cells. Intact cell 
measurements offer distinct differences when compared to lysates in that the cell 
compartments and protein/organelle spatial relationships remain intact, providing an assay 
environment that is more biologically relevant than a lysate. Peptide X-A was easily 
introduced into intact cells using pinocytic loading and the cell with peptide incubated for 25 
min prior to assay. Under these conditions, peptide X-A was readily phosphorylated (23.5 
± 1.4%) in intact cells over the 25 min assay time. The peptide was also degraded in the 
intact cells into 5 different fragments (Figure 5), with the 5-mer fragment forming in the 
highest amounts, accounting for 21 ± 2% of all peptide. Of the 5 fragment peptides formed 
within the intact cells, only two (the 4-mer and 5-mer fragments) are the same as those 
formed in lysates, indicating that different peptidases are activated in the intact cells. The 
remaining three fragments that formed in the intact cells are the 7-, 9-, and 10-residue 
fragment peptides.
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Small peptides are generally less specific for kinases than the full-length protein substrates 
due to their lack of the 3D structure and absence of accessory binding sites. To determine 
how well X-A behaves as a specific BCR-ABL substrate, the specificity of X-A for BCR-
ABL was evaluated using a small panel of tyrosine kinase inhibitors. Imatinib and dasatinib 
inhibit BCR-ABL, c-KIT, and PDGFR at similar concentrations.53 Masitinib was developed 
as a c-KIT inhibitor and only impacts BCR-ABL at micromolar concentrations.39 Sunitinib 
is a potent inhibitor of VEGF and PDGF receptors and is not known to affect BCR-ABL at 
concentrations used to block VEGF and PDGF.54 Inhibitors were used at 5× the IC50 
concentrations for their target kinases37-40 and inhibitor activity was verified by incubation 
with purified ABL-1 and measurement of X-A phosphorylation (Supplemental Figure S6). 
Cells were incubated with a tyrosine kinase inhibitor and then pinocytically loaded with X-A 
followed by measurement of X-A degradation and phosphorylation. The inhibitors did not 
impact degradation of X-A by cytosolic proteases (Figure 5A-B). Both imatinib and 
dasatinib significantly decrease the amount of X-A phosphorylation to 5.7 ± 0.3% and 3.7 
± 0.9%, respectively (p < 0.001 when compared to the DMSO vehicle). Masitinib also 
decreases phosphorylation of X-A relative to the control (p < 0.05). Suntinib does not 
significantly alter phosphorylation of X-A by the cell lysate. Taken together these results 
suggest that under these conditions, the major kinase phosphorylating X-A is BCR-ABL. X-
A acts as a long-lived BCR-ABL kinase reporter in these cells.
CONCLUSION
We have demonstrated the rational design of a BCR-ABL substrate reporter resistant to 
peptidase degradation that provides a direct readout of BCR-ABL activity in cellular lysates 
and intact cells. The bonds most susceptible to proteolysis were sequentially identified and 
flanking amino acids were replaced with non-native amino acids to yield increasingly stable 
substrates. The longer lifetime of the modified peptide enables the substrate to be loaded 
into intact cells followed by measurement of BCR-ABL activity within those cells. 
Utilization of a small panel of tyrosine kinase inhibitors strongly suggests that in these cells 
the reporter acts to report BCR-ABL activity as opposed to the activity of other kinases. A 
future goal of this project will be to optimize delivery into intact, single cells for assay of 
single-cell kinase activity, for example by generating a membrane-permeant version of the 
reporter
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Figure 1. 
Properties of the series VIII peptides. (A) Degradation in a Baf/BCR-ABL cellular lysate. 
(B) In vitro phosphorylation with purified Abl-1 kinase. The symbols are defined as: black 
filled square (peptide III-67B), red open circle (peptide V-48B), blue closed triangle (peptide 
VIII-A), green open triangle (peptide VIII-B), and purple open square (peptide VIII-C).
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Figure 2. 
Electropherograms of peptide IX-A incubated in a Baf/BCR-ABL cytosolic lysate for 0 (A), 
30 (B), or 60 (C) min. The electrophoretic buffer utilized was 100 mM tris, 100 mM tricine, 
pH 8.1. Degradation of IX-A and formation of peptide fragments over time (D). The 
symbols are defined as follows: black closed square (peptide xii), red open circle (peptide 
xi), blue open triangle (peptide vi), pink open square (peptide v), green open diamond 
(peptide iii). (E) The uppercase letters are the single amino acid abbreviations for peptide 
IX-A’s sequence, with Sarc the abbreviation for sarcosine, and MePh the abbreviation for N-
methyl phenylalanine. The roman numerals indicate the cleavage locations that generated 
the indicated peptide fragment.
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Figure 3. 
Properties of the IX-A and X-A peptides. (A) Percentage of intact peptide in a Baf/BCR-
ABL cellular lysate. (B) In vitro phosphorylation of the peptides with purified Abl-1 kinase. 
The symbols are defined as: black filled square (peptide III-67B), red open circle (peptide 
V-48B), pink open triangle (peptide IX-A), and blue open diamond (peptide X-A).
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Figure 4. 
Electropherograms of peptide X-A incubated in a Baf/BCR-ABL cytosolic lysate for 0 (A), 
30 (B), or 60 (C) min. The electrophoretic buffer utilized was 100 mM tris, 100 mM tricine, 
5 mM SDS, pH 8.1. (D) The percentage of X-A present as intact X-A and peptide fragments 
is shown over time. The symbols are defined as follows: black closed square (peptide xi), red 
open circle (peptide v), blue closed triangle (peptide iv), pink open square (peptide ii), green 
open diamond (peptide i). (E) The uppercase letters are the single amino acid abbreviations 
for peptide X-A’s sequence, with Sarc the abbreviation for sarcosine, and MePh the 
abbreviation for N-methyl phenylalanine. The roman numerals indicate the cleavage 
locations that generate the indicated peptide fragment.
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Figure 5. 
Select electropherograms from pinocytically loaded cells treated with DMSO vehicle (A) or 
dasatinib (B) prior to loading. Phosphorylated X-A (pX-A) is indicated by the arrow and the 
roman numerals are the fragments identified for peptide X-A in Figure 4. The 
electrophoretic buffer utilized was 100 mM tris and 100 mM tricine, pH 8.8. (C) 
Phosphorylation of peptide X-A in Baf/BCR-ABL cells pre-treated with or without tyrosine 
kinase inhibitors. *** P-value ≤ 0.001 and * P-value ≤ 0.05 when compared to the DMSO 
control.
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Table 1
Properties of the peptides tested.
Peptide Name Sequence t1/2
a
 (min) t50% Pb (min)
III-67B* 5FAM-GGAYAAPFKKKA 1.3 190
V-48B* 5FAM-GGIYAAP-MePhe-KKKA 19.4 400
VII-A 5FAM-GGIY-MeAla-AP-MePhe-KKKA 1.6 NP
VII-B 5FAM-GGIY-Sarc-AP-MePhe-KKKA 5.5 NP
VII-C 5FAM-GGIY-DAla-AP-MePhe-KKKA 17.9 NP
VIII-A 5FAM-GGIYA-MeAla-P-MePhe-KKKA 25.8 68
VIII-B 5FAM-GGIYA-Sarc-P-MePhe-KKKA 48.7 650
VIII-C 5FAM-GGIYA-DAla-P-MePhe-KKKA 5.1 >100,000
IX-A 5FAM-GGIYA-Sarc-P-MePhe-KKK 32.1 232
X-A 5FAM-GGIYA-Sarc-P-MePhe-KKK-COOH 110 945
*
Data from previous work.30
a
t1/2 is the time at which 50% of the peptide was degraded in the cytosolic lysate (3 mg mL−1 total protein).
b
t50% P is the time required for 50% of the peptide to be phosphorylated by Abl-1 kinase under the conditions employed using 12 nM of kinase. 
NP indicates no phosphorylation occurred. Peptides are amidated on the C-terminus unless noted otherwise. Abbreviations are the standard single 
letter amino acids, except for the following: MePhe (N-methylated phenylalanine), MeAla (N-methylated alanine), Sarc (sarcosine), DAla (D-
alanine).
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